CRISPR

CRISPR2-cox7a1

ID

ZDB-CRISPR-240320-15

Name

CRISPR2-cox7a1

Previous Names

cox7a1 sgRNA2 (1)

Target

cox7a1 (1)

Sequence

5' - AGGAAAATTTTCTGTTTCTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
brn6	cox7a1

Expression

Gene expression in Wild Types + CRISPR2-cox7a1

No data available

Phenotype

Phenotype resulting from CRISPR2-cox7a1

No data available

Phenotype of all Fish created by or utilizing CRISPR2-cox7a1

Phenotype	Fish	Conditions	Figures
skeletal muscle formate increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart glycerophosphocholine increased amount, abnormal	cox7a1^brn6/brn6	amputation: cardiac ventricle	Fig. 6 from Garc�a-Poyatos et al., 2024
regenerating tissue proliferative region increased amount, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
heart formate increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
heart alanine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
whole organism mitochondrion Ab1-uqcrc2 labeling decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 1 from Garc�a-Poyatos et al., 2024
skeletal muscle adenosine 5'-monophosphate decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle calcium cation increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 2 from Garc�a-Poyatos et al., 2024
swimming behavior decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024
heart alanine increased amount, abnormal	cox7a1^brn6/brn6	amputation: cardiac ventricle	Fig. 6 from Garc�a-Poyatos et al., 2024
whole organism regulation of oxidative phosphorylation decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 1 from Garc�a-Poyatos et al., 2024
heart striated muscle cell differentiation decreased process quality, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
skeletal muscle regulation of oxidative phosphorylation decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 1 from Garc�a-Poyatos et al., 2024
heart mitochondrial crista decreased width, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 2 from Garc�a-Poyatos et al., 2024
skeletal muscle extracellular matrix assembly decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024
heart methionine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
skeletal muscle UDP-D-glucose decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle fructose 6-phosphate decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart methionine increased amount, abnormal	cox7a1^brn6/brn6	amputation: cardiac ventricle	Fig. 6 from Garc�a-Poyatos et al., 2024
cardiac ventricle regenerating tissue ab1-n2.261 labeling increased amount, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
skeletal muscle methionine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart mitotic cell cycle phase transition decreased process quality, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
heart glycine increased amount, abnormal	cox7a1^brn6/brn6	amputation: cardiac ventricle	Fig. 6 from Garc�a-Poyatos et al., 2024
heart positive regulation of vasculature development decreased process quality, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
skeletal muscle histidine decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart cellular response to oxidative stress decreased process quality, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
cardiac ventricle regenerating tissue ab1-mef2 labeling increased amount, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
whole organism mitochondrion Ab2-ndufs3 labeling decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 1 from Garc�a-Poyatos et al., 2024
calcium-mediated signaling increased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024
skeletal muscle mitochondrial crista decreased width, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 2 from Garc�a-Poyatos et al., 2024
skeletal muscle isoleucine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle lysine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart positive regulation of cell projection organization decreased process quality, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
whole organism decreased weight, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024
skeletal muscle ATP decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle D-glucose 6-phosphate decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle leucine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
NADH dehydrogenase (ubiquinone) activity increased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
heart calcium cation increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 2 from Garc�a-Poyatos et al., 2024
pyruvate metabolic process decreased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart glycerophosphocholine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
carbohydrate catabolic process decreased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle decreased width, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024
skeletal muscle glycine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle N-phosphocreatine decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart valine increased amount, abnormal	cox7a1^brn6/brn6	amputation: cardiac ventricle	Fig. 6 from Garc�a-Poyatos et al., 2024
tricarboxylic acid cycle decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
ubiquinol-cytochrome-c reductase activity increased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
response to nutrient decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart formate increased amount, abnormal	cox7a1^brn6/brn6	amputation: cardiac ventricle	Fig. 6 from Garc�a-Poyatos et al., 2024
heart mitochondrial chromosome decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 2 from Garc�a-Poyatos et al., 2024
heart skeletal muscle decreased mass, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 5 from Garc�a-Poyatos et al., 2024
fatty acid oxidation decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
skeletal muscle glycoprotein decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle sarcomere decreased thickness, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 , Fig. 5 from Garc�a-Poyatos et al., 2024
skeletal muscle polysaccharide decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
heart phosphocholine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
skeletal muscle lactate decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
glycolytic process decreased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle tyrosine decreased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
skeletal muscle valine increased amount, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 4 from Garc�a-Poyatos et al., 2024
cytochrome-c oxidase activity decreased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 6 from Garc�a-Poyatos et al., 2024
muscle contraction increased occurrence, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024
regenerating tissue connective tissue replacement involved in inflammatory response wound healing decreased occurrence, abnormal	cox7a1^brn6/brn6	cryoablation: cardiac ventricle	Fig. 7 from Garc�a-Poyatos et al., 2024
skeletal muscle sarcomere disorganized, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 5 from Garc�a-Poyatos et al., 2024
mitochondrial calcium ion transmembrane transport decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 5 from Garc�a-Poyatos et al., 2024
actin filament organization decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 5 from Garc�a-Poyatos et al., 2024
skeletal muscle mitochondrial respirasome assembly decreased process quality, abnormal	cox7a1^brn6/brn6	standard conditions	Fig. 3 from Garc�a-Poyatos et al., 2024

Citations